Newsroom

HOUSTON--(BUSINESS WIRE)--Representatives from the Federal Home Loan Bank of Dallas (FHLB Dallas), Home Bank and Bread of Life, Inc. gathered with community partners today to celebrate the grand opening and ribbon cutting of the Knowles-Rowland House, a new 31-unit permanent supportive housing development serving individuals exiting homelessness. The project was supported in part by a $500,000 Affordable Housing Program (AHP) grant awarded by FHLB Dallas through member institution Home Bank.Know...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Forrester Research, Inc. (Nasdaq: FORR) will broadcast its third-quarter earnings conference call at 4:30 p.m. ET on October 29, 2026. The call will be available at Forrester.com. Investors who wish to hear the call should log on at least 15 minutes prior to the broadcast. Participants may pre-register for the call here. Instructions are provided to ensure that the necessary audio applications are downloaded and installed. Users can obtain these programs at no...

WASHINGTON--(BUSINESS WIRE)--CAGW's Prime Cuts 2026 is a list of comprehensive recommendations to eliminate waste, fraud, abuse, and mismanagement in the federal government. ...

NASHVILLE, Tenn.--(BUSINESS WIRE)--VOCE Hotel and Residences released new renderings of its exclusive penthouse residences at mixed-use tower under construction in Midtown Nashville....

LONDON--(BUSINESS WIRE)--  Xtrackers (IE) plc Investment Company with Variable Capital Registered Office: 78 Sir John Rogerson's Quay, Dublin 2, Ireland Registration number: 393802 (the “Company”) NOTICE TO SHAREHOLDERS OF THE SUB-FUNDS LISTED ON THE LONDON STOCK EXCHANGE Dublin, 14 October 2026 This announcement is to inform the shareholders of the sub-funds listed in the table below (each a Sub-Fund, and together the Sub-Funds) (the Shareholders) on behalf of the board of directors of the Com...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Reservoir today launched a personal cell preservation service that lets adults preserve their own immune cells through a standard blood draw. Reservoir is available today through partner clinics in San Francisco, Boston, Los Angeles, and New York City, with in-home appointments launching in select markets. Sign up at withreservoir.com to be matched with a nearby appointment or to receive updates when Reservoir comes to your city. To see Reservoir in action, go...

LONDON--(BUSINESS WIRE)--  Xtrackers II Investment company with variable capital (Société d'investissement à capital variable) Registered office: 49, avenue J.F. Kennedy, L-1855 Luxembourg R.C.S. Luxembourg B-124.284 (the “Company”) NOTICE TO SHAREHOLDERS OF THE SUB-FUNDS LISTED ON THE LONDON STOCK EXCHANGE Luxembourg, 14 October 2026 The board of directors of the Company (the “Board of Directors”) hereby informs all shareholders of the sub-funds listed in the table below (each a “Sub-Fund”, an...

WASHINGTON--(BUSINESS WIRE)--Sterne, Kessler, Goldstein & Fox (Sterne Kessler), a market leading intellectual property (IP) law firm, today announced a co-development partnership with Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, to develop AI-enhanced patent workflow solutions. This partnership brings together Sterne Kessler’s practitioner-built technology and deep patent practice expertise with Clarivate’s leading IP data and software. Together, the...

LONDON--(BUSINESS WIRE)--  Xtrackers Investment company with variable capital (Société d'investissement à capital variable) Registered office: 49, avenue J.F. Kennedy, L-1855 Luxembourg R.C.S. Luxembourg B-119.899 (the “Company”) NOTICE TO SHAREHOLDERS OF THE SUB-FUNDS LISTED ON THE LONDON STOCK EXCHANGE Luxembourg, 14 October 2026 The board of directors of the Company (the “Board of Directors”) hereby informs all shareholders of the sub-funds listed in the table below (each a “Sub-Fund”, and t...

OSAKA, Japon et CAMBRIDGE, Massachusetts--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) a annoncé les résultats détaillés de l'essai clinique pivot IgGNITE de phase 2/3 (TAK-881-3001) évaluant le TAK-881 expérimental [immunoglobuline sous-cutanée (humaine), solution à 20 % (SCIG 20 %) et hyaluronidase humaine recombinante], qui, s'il est approuvé, pourrait devenir le premier traitement facilité par SCIG 20 % pour les patients atteints d'un déficit immunitaire primitif (DIP) administré jusqu'à une...